{
    "clinical_study": {
        "@rank": "110954", 
        "arm_group": [
            {
                "arm_group_label": "Glucagon level: 0,11 and 1 mg", 
                "arm_group_type": "Experimental", 
                "description": "Glucagon level: 0,11 and 1 mg"
            }, 
            {
                "arm_group_label": "Glucagon level: 0,22 and 0,66 mg", 
                "arm_group_type": "Experimental", 
                "description": "Glucagon level: 0,22 and 0,66 mg"
            }, 
            {
                "arm_group_label": "Glucagon level: 0,44 and 0,33 mg", 
                "arm_group_type": "Experimental", 
                "description": "Glucagon level: 0,44 and 0,33 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and\n      glucagon) substituting for the pancreas and facilitating tight euglycemic control in\n      patients with T1DM."
        }, 
        "brief_title": "Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is planned as open, randomised 3-period cross-over in patients with T1DM. The\n      study will include a total of 6 completing patients. The study is not blinded due to the\n      exploratory nature.\n\n      At each of the 3 periods, different blood glucose level will be established in 4 steps (8,\n      6, 4, and 2.8 mmol/L), and a prefixed glucagon dose will be given per glucose level. The\n      sequence of glucagon dose strength for the three dosing days will be randomized."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects with diabetes mellitus type 1 , as defined by the American\n             Diabetes Association1.\n\n          -  Age \u2265 18 and \u2264 65 years.\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to trial product(s) or related products.\n\n          -  Receipt of any investigational medicinal product within 3 months or 5 half-lives of\n             that IMP before randomisation in this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916265", 
            "org_study_id": "PCDiab01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Glucagon level: 0,11 and 1 mg", 
                "Glucagon level: 0,22 and 0,66 mg", 
                "Glucagon level: 0,44 and 0,33 mg"
            ], 
            "intervention_name": "Glucagon", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "state": "NRW", 
                    "zip": "41460"
                }, 
                "name": "Profil Institut f\u00fcr Stoffwechselforschung GmbH"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Single Center, Three-period Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages at Four Different Blood Glucose Concentrations", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "AUCGlucose of different glucagon dosages given s.c.", 
            "safety_issue": "No", 
            "time_frame": "90 min after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Profil Institut f\u00fcr Stoffwechselforschung GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "European Union", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Profil Institut f\u00fcr Stoffwechselforschung GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}